CCX168
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin A Nephropathy
Conditions
Immunoglobulin A Nephropathy
Trial Timeline
Mar 27, 2015 → Jun 1, 2018
NCT ID
NCT02384317About CCX168
CCX168 is a phase 2 stage product being developed by Amgen for Immunoglobulin A Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02384317. Target conditions include Immunoglobulin A Nephropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05988021 | Phase 1 | Completed |
| NCT02464891 | Phase 2 | Terminated |
| NCT02384317 | Phase 2 | Completed |
Competing Products
11 competing products in Immunoglobulin A Nephropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| zigakibart | Novartis | Phase 2 | 52 |
| iptacopan | Novartis | Phase 3 | 77 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Rilzabrutinib + Placebo + Glucocorticoid | Sanofi | Phase 3 | 76 |
| rilzabrutinib + Glucocorticoids | Sanofi | Phase 2 | 51 |
| Felzartamab | Biogen | Phase 2 | 49 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |